ranibizumab |
5 |
age-related macular degeneration |
4 |
half-dose |
4 |
half-fluence |
4 |
photodynamic therapy |
4 |
polypoidal choroidal vasculopathy |
4 |
verteporfin |
4 |
adult |
3 |
aged |
3 |
best corrected visual acuity |
3 |
blindness |
3 |
clinical article |
3 |
controlled study |
3 |
conventional glycemic control |
3 |
diabetes |
3 |
diabetic retinopathy |
3 |
dietary supplement |
3 |
inflammation |
3 |
insulin dependent diabetes mellitus |
3 |
intense glycemic control |
3 |
nanotechnology |
3 |
natural product |
3 |
neovascularization |
3 |
non insulin dependent diabetes mellitus |
3 |
oxidative stress |
3 |
retina |
3 |
vessel |
3 |
aflibercept |
2 |
macular degeneration |
2 |
phacoemulsification |
2 |
phacovitrectomy surgery |
2 |
premium intraocular lens |
2 |
vascular endothelial growth factors |
2 |
vitrectomy |
2 |
anti-vegf |
1 |
choroidal neovascularization |
1 |
extra-pulmonary tb |
1 |
mycobacterium tuberculosis |
1 |
myopia |
1 |
ocular tuberculosis |
1 |
ocular uveitis |
1 |
tb uveitis |
1 |